Introduction
The development of drugs for treating central nervous system (CNS) disorders is a medically challenging and commercially risky field, which is known to have a high attrition rate [1] . The blood-brain barrier (BBB), which is a major interface between the circulatory system and the brain parenchyma, can hinder a drug candidate's access to pharmacological targets located within the brain parenchyma. As brain capillaries are the main entry route for the CNS, they can therefore also prevent neuropharmaceuticals from reaching the brain parenchyma at an effective dose. Consequently, the therapeutic potential of a drug candidate is not only related to its activity at the target, but also to its ability to attain an effective dose at the target site. Ideally, this issue should be addressed as early as possible in the drug discovery process [2] .
Since animal-based assays tend to be time-consuming and require bioanalytical input or access to radiolabelled compounds, they are generally performed at a relatively late stage of development and are not particularly suitable for dealing with the flow of compounds generated by combinatorial chemistry and high-throughput screening. To overcome the limitations of such in vivo studies, several animal-free techniques have been developed since the early 90′s for determining the BBB permeability of potential drug candidates [3] . In vitro BBB permeability is usually quoted as the endothelial permeability coefficient https://doi.org/10.1016/j.ejpb.2018.03.007 Received 27 October 2017; Received in revised form 13 February 2018; Accepted 16 March 2018 (P e ) or apparent permeability value (P app ) and converted to the permeability surface area product (PS) that represents the clearance across the BBB into the brain.
In many cases, the intended use of in vitro BBB permeability in the drug discovery process is to predict whether investigational drugs are likely to achieve a relevant CNS concentration to elicit the desired pharmacological effect. However, BBB permeability is a measurement of the rate of drug delivery to the CNS (i.e. speed at which compounds cross the BBB) which must be considered separately from the extent (e.g. the ratio of drug concentration in brain and plasma) of equilibration of the drug across the BBB and the intra-brain distribution data in order to fully understand brain drug delivery and its consequences for central drug action [4] .
Therefore, care should be taken when interpreting results of correlations between in vitro and in vivo models and when comparing different in vitro or in vivo approaches, as there can be many reasons for divergent results [5] . For instance, in the past, the extent and the rate of transport (i.e. BBB permeability) have sometimes been compared and used indiscriminately [6] . Furthermore, since 2002, methods have been developed to estimate drug binding to brain tissue, usually expressed as the fraction unbound brain (f u,br , i.e. the ratio of the amount of free drug in the interstitial fluid divided by its total amount in brain tissue). The availability of high-throughput equilibrium dialysis [7, 8] or brain slice methods [9] to estimate a drug's f u,br has highlighted that the in vivo BBB permeability (i.e. the rate of drug delivery to the CNS) is influenced by their ability to bind to brain tissue [6, 10, 11] . Consequently, as in vitro experimental designs can fail to take into account binding to brain tissue [6, 12] , this might confound the interpretation of data and generate misleading correlations and conclusions when comparisons between in vitro and in vivo models are made.
The well-tested rodent in-situ brain perfusion method [13] enables an accurate assessment of BBB permeability in vivo and could therefore be considered as an ideal validation tool for assessing in vitro BBB models.
In collaboration with AstraZeneca (DMPK department, Södertälje, Sweden) the in vitro permeability (P app and P e ) of 27 marketed CNS drugs has been determined using a bovine in vitro BBB model, adapted to high-throughput screening [14] , and compared to their in vivo permeability (P vivo ), obtained by rat in-situ brain perfusion. The latter was taken from published data by Summerfield et al. (2007) [6] . The selected CNS compounds are covering a wide range of physico-chemical properties and the relationship between their BBB permeability in vitro and their binding to brain tissue (based on published f u,br ) was examined in this study. For this, a new method to assess in vitro permeability (P vitro ) was used, as it implements brain tissue binding in the assay.
Material and methods

Test compounds
The marketed CNS compounds were obtained from Sigma-Aldrich (Stockholm, Sweden), except for risperidone, olanzapine, saquinavir, donepezil, venlafaxine and ziprasidone, which were obtained from Sequoia Research Products (Pangbourne, UK). [U-
14 C]-Sucrose was obtained from Perkin-Elmer (Waltham, MA, USA). All other compounds were provided by AstraZeneca R&D, Södertälje, Sweden from in-house sources. Reagents were obtained from Sigma-Aldrich (Stockholm, Sweden). All compounds were dissolved at a concentration of 2 µM in KrebsRinger HEPES buffer (NaCl 150 mM, KCl 5.2 mM, CaCl 2 2.2 mM, MgCl 2 0.2 mM, NaHCO 3 6 mM, Glucose 2.8 mM, HEPES 5 mM, water for injection).
2.2. Traditional method to assess in vitro BBB permeability (apparent permeability, P app and endothelial permeability, P e )
The traditional method for assessing the in vitro BBB permeability is taken from the co-culture model of [15] , which was slightly modified as described by Culot et al. (2008) [14] to adapt it to industrial high-throughput screening requirements. In brief, primary bovine brain capillary endothelial cells (bBCECs) were seeded at 6 × 10 5 cells·mL −1 on a semi-permeable membrane (0.4 μm, 24-well system, Millicell-24 cell culture insert plate, Millipore Corporation, MA, USA) coated with rat tail collagen (prepared by using the method of Bornstein (1958) [16] , and placed in a single-well feeding cell culture plate (Millipore Corporation, MA, USA). After 3 days, medium was changed to BBB inducing medium (containing 1% of conditioned medium from the traditional glial and EC co-culture) (Cellial Technologies, Lens, France). Drug in vitro permeability assessment was carried out 1 day later at pH = 7.4 and T = 37°C. At the initiation of the permeability experiments, the receiver wells of a cell-free 24-well plate were filled with 0.8 mL buffered Ringer's solution and filter inserts containing confluent monolayers of bBCEC, were placed in the 24-well plate. The test solution, containing the compound at 2 µM, was added to the bBCEC monolayer at a volume of 0.4 mL and the plate was placed on an orbital shaker (model PX-MIS 6-1, Polymix, Kinematica AG, Switzerland) with low shaking velocity (60 rpm) for exactly 30 min. In parallel, the integrity of the bBCEC monolayer was assessed by permeability measurements of either 14 C-sucrose (1.813 kBq·mL
) or lucifer yellow (50 μM). Aliquots were taken from the donor solution in the beginning of the experiment (C 0 ) and from the donor and receiver compartment at the end of the experiment. A total of 3 inserts with and 3 inserts without cells were assessed for each test compound.
The in vitro brain permeability was measured by either the calculation for P app (cm·s (Eq. (4)). The P app was calculated as followed:
With J representing the flux or rate of appearance of the compound in the receiver compartment (amount·s ); and S, the surface area of the filter insert, which is 0.7 cm 2 for the 24-well format. This results in cm·s −1 as the unit for P app .
The P e was calculated as described by Siflinger-Birnboim et al. [17] . By dividing the amount of compound in the receiver compartment by the drug concentration in the donor compartment (Eq. (2)), the cleared volume (CL in μL) was obtained at each time point.
With A receiver representing the amount of the compound in the receiver compartment; and C donor , the concentration of the compound in the donor compartment.
When the average cumulative CL is plotted over time, the slope equals the permeability surface area product (PS) of the filter. The PS of a filter coated with bBCECs is called the total PS (PS t ) and the PS of a filter without bBCECs is called the filter PS (PS f ). The PS value for the bBCEC monolayer (PS e ) can be computed out of PS t and PS f (Eq. (3)). Units of PS and surface area are μL·min −1 and cm 2 , respectively.
To generate P e (cm·min −1 ), the PS e value was divided by the surface area of the filter.
To assess possible adsorption to plastic or non-specific binding to cells, the mass balance (MB, %) was calculated by the amount of recovered compound in both compartments at the end of the experiment divided by the total amount of compound added in the donor compartment at t 0 .
New method to assess in vitro BBB permeability (P vitro )
The new in vitro permeability (P vitro ) was obtained by using the same protocol as the traditional method explained above, but with some modifications in experimental design and calculation method.
Primary cultures of mixed glial cells (GC) were prepared from the cerebral cortex of new-born rats. After removing the meninges, the brain tissue was forced gently through a nylon sieve. Glial cells were plated on 6-well dishes (Nunc, Roskilde, Denmark) at a concentration of 1.2 × 10 5 cells·mL −1 in 2 mL DMEM supplemented with 10% (v/v) fetal calf serum (Hyclone Laboratories). The medium was changed twice a week. Three weeks after seeding, cultures of GC were stabilized and composed of astrocytes (60%, characterized with glial fibrillary acidic protein), oligodendrocytes (30%, characterized with O4) and microglial cells (10%, characterized with ED-1).
As explained above, 1 × 10 6 cells of bBCECs were seeded on a gelatin-coated Petridish (100 mm diameter, Corning). After 2 days, the bBCECs were subcultured in Transwell inserts (0.4 μm pore size, 6-well system, Corning Incorporate) coated with rat tail collagen and placed in a, with stabilized primary rat GC seeded, 6-well. After 12 days in the incubator at 37°C and 5% CO 2 , drug in vitro permeability assessments were carried out at pH = 7.4 and T = 37°C. At the initiation of the permeability experiment, the receiver wells of a 6-well plate containing the primary rat GC, were rinsed twice with 5 mL and filled with 2.5 mL buffered Ringer's solution and Transwell inserts containing confluent monolayers of bBCECs, were placed in the 6-well plate. The test solution, containing the compound at 2 µM, was added to the bBCEC monolayer at a volume of 1.5 mL and the plate was placed on an orbital shaker (model PX-MIS 6-1, Polymix, Kinematica AG, Switzerland) with low shaking velocity (60 rpm) for exactly 60 min. In parallel, the integrity of the bBCEC monolayer was assessed by permeability measurements of either 14 C-sucrose (1.813 kBq·mL) or lucifer yellow (50 μM). Aliquots were taken from the donor solution in the beginning of the experiment (C donor,0 ) and from the donor and receiver compartment at the end of the experiment. A total of 3 inserts with and 3 inserts without cells were assessed for each test compound. All samples were analysed using tandem mass spectrometry (cfr. Analytical procedures) and raw data were computed using the bluenorna® calculator to generate P vitro (cm·min −1 ) according to the following equations (Eqs. (5) and (6)):
Where C donor (in mM) is the concentration of compound in the donor compartment at either the onset or end of the transport experiment, T (in min) is the duration of the permeability experiment, V donor (in mL) is the volume of the donor compartment, which is 1.5 mL and S is the surface area of the Transwell insert (i.e. 4.67 cm 2 ).
Analytical procedures
The amount of the radiolabel ( 14 C-sucrose) and fluorescent label (lucifer yellow) were determined by liquid scintillation (Packard Instrument Company, Meriden, USA) and fluorescence spectrophotometry (Synergy H1, BioTek Instruments SAS, Colmar, France), respectively. For the measurement of lucifer yellow, an excitation wavelength of 432 and an emission wavelength of 538 were used. A blank value was subtracted from the measured values. All CNS compounds were determined by the liquid chromatography -mass spectrometry (LC/MS) method. All samples were analysed using the following instruments: mass spectrometer, Quattro Premier XE (Waters); autosampler, acquity sample manager; UPLC pump, acquity binary solvent manager (Waters); robot for sample preparation, Biomek FX (Beckman-Coulter). The following chemicals and reagents were used: ammonium acetate (Merck), acetonitrile gradient grade (Merck), methanol gradient grade (Merck), laboratory deionised water, further purified with a Milli-Q water purifying system and ammonium acetate 1 mol/L in milli-Q water. Samples were stored in −20°C. Prior to analysis, samples were thawed and shaken. If re-analysis was necessary, samples were stored overnight at 10°C (in an auto sampler).
For chromatography, the following system was used: analytical column, acquity UPLC BEH C18 1.7 μm, 2.1 × 30 mm (Waters). Eluent A was 10 mM ammonium acetate containing 2% acetonitrile and Eluent B was 10 mM ammonium acetate containing 80% acetonitrile. The flow rate was 0.6 mL·min −1 (loop: 10 µL, injection volume: 5-10 µL). The gradient started at 0.2 min with 2% of Eluent B and increased to 100% of Eluent B within 0.3 min followed by a column washing step at 100% of Eluent B for 0.2 min. Quantification of unknown samples was performed, using QuanLynx software. Response factors were constructed by plotting peak area of the analyte against concentration of each analyte using an average response factor of the donor (D 0 /C 0 ) sample injections. The average RF function without weighting was used.
Results and discussion
In this study, the in vitro BBB transport of 27 CNS compounds has been assessed and the relationship between either their P app or P e values in vitro and their in vivo permeability was compared. To evaluate the influence of brain tissue binding in BBB transport, the compounds were arbitrarily classified in four categories of f u,br (Table 1) . Both in vivo permeability and f u,br data were obtained from one single study of Summerfield et al. (2007) [6] (Table 2) .
Several authors tend to use the P app calculation when assessing BBB permeability, while other used the P e calculation, which also accounts for the ability of the compound to cross the cell culture insert. The latter therefore required the assessment of the permeability of the compounds over inserts without cells (PS f ).
Although the ability of the compounds to cross the filter is not accounted for in the P vitro calculation, the distribution of the compounds across similar collagen coated inserts (i.e. 6 well-system) without cells has been assessed. All compounds were considered to not be limited by their ability to cross the coated insert. This was based on the sufficient amount of compounds found in the receiver compartment at the end of the one hour transport experiment (i.e. more than 20% of initial amount -data not shown).
As exposure to CNS drugs might affect the tightness of the in vitro BBB during the BBB permeability assessment of the drug, the integrity of the bBCEC monolayer during the drug permeability experiment was assessed in parallel by the permeability assessment of either the radiolabel 14 C-sucrose or the fluorescent label lucifer yellow. All presented BBB permeability results correspond to experiments where P e for the marker molecule(s), in presence of the tested compounds, did not result in a significant increase compared to a control experiment without the tested compounds.
3.1. Relationship between P app and P e with P vivo for compounds with decreasing f u,br
We evaluated the relationship between BBB permeability in vitro (i.e. P e and P app ) and in vivo (i.e. P vivo ) for compounds with decreasing f u,br. The latter data (i.e. P vivo ) was coming from literature [6] .
Strong correlations between P vivo and, either in vitro P app (Fig. 1A) or P e (Fig. 1B) , are obtained for compounds characterized by an f u,br > 0.1 (n = 6, R 2 = 0.78, p = 0.0204 for P app ; and n = 6, R 2 = 0.93, p = 0.0017 for P e ) and f u,br > 0.05 ( Fig. 1C and D, n = 11, R 2 = 0.60, p = 0.0052 for P app ; and n = 11, R 2 = 0.80, p = 0.0002 for P e ).
The stronger correlation between P vivo and P e than between P vivo and P app confirms previous works and supports the use of the P e calculation in such study [14, 18] . The good correlation between in vitro and in vivo permeability confirms previous findings showing that this in vitro BBB model is highly predictive for the in vivo rate of brain penetration for several CNS compounds [14] .
However, the same correlation appears very weak after the inclusion of compounds into the dataset characterized by an f u,br between 0.05 and 0.01 ( Fig. 1E and F , n = 18, R 2 = 0.42, p = 0.0036 for P app ;
and n = 18, R 2 = 0.38, p = 0.066 for P e ). No correlation is shown after the inclusion of compounds with an f u,br < 0.01 ( Fig. 1G and H, n = 27, R 2 = 0.02, p = 0.4900 for P app ; and n = 27, R 2 = 0.005, p = 0.7296 for P e ).e 3.2. Relationship between P vivo /P app and P vivo /P e and f u,br
The observed discrepancies between P vivo and in vitro P e or P app for compounds with low f u,br corroborates what has been published by several other investigators i.e. that in vivo permeability is a composite function of both permeability across the BBB and brain tissue binding, whereas in vitro permeability uncouples non-specific binding (Fig. 2 ) [6] . An important note here is that the perfusate used to determine the in vivo permeability is Krebs-Ringer HEPES buffer, and therefore, P vivo does not account for plasma protein binding.
Indeed, it can be observed that the lack of correlation is mainly due to several lipophilic compounds characterized by high tissue binding. This indicates that brain tissue binding may confound actual in vivo permeability in-situ and that the observed low in vitro permeability for [6] , and in vitro BBB permeability, either depicted by the apparent permeability (P app ) (Graph A, C, E and G), or by the endothelial permeability (P e ) (Graph B, D, F and H), and this for compounds of decreasing f u,br .
these compounds may be a true reflection of their diffusion process across the BBB. This is supported by the relationship between f u,br and P vivo /P app (Fig. 3A , n = 27, R 2 = 0.64, p < 0.0001) or by the relationship between f u,br and P vivo /P e (Fig. 3B , n = 27, R 2 = 0.70, p < 0.0001). Based on previous findings i.e. that discrepancies between P vivo and in vitro permeability is related to brain tissue binding, we have developed a new in vitro method to obtain the in vitro permeability which accounts for brain tissue binding, P vitro . This new in vitro method, and the corresponding parameter, therefore improves the predictive power of the in vitro assay. This new method is based on the presence of glial cells (GC) in the receiver compartment to mimic the effect of brain tissue binding in vivo during the permeability experiment (Fig. 4A) .
Relationship between P vivo and P vitro
In comparison to P app and P e , the correlation between P vitro and P vivo for all 27 compounds is significantly improved (Fig. 4B , n = 27, R 2 = 0.72, p < 0.0001). This highlights the interest of the introduced new method as no correlation was found between P vivo and in vitro P app or P e for the same dataset, consisting of compounds with different physico-chemical properties and f u,br (Table 3) (Fig. 1G and H) .
The new calculation method is based on the compound's clearance from the donor compartment with the assumption that the cleared compound is entering the brain.
To further evaluate the impact of GC in the in vitro BBB model during the permeability experiment, and to rule out that the observed difference between P vitro and P e was solely attributed to the different Fig. 2 . Differences in f u,br depending on the experimental design of the model: A) In-situ rat BBB model, B) In vitro bovine BBB model (consisting of bBCEC) without glial cells (GC) in the receiver compartment during the drug permeability experiment; and C) In vitro BBB model (consisting of bBCEC) with GC in the receiver compartment during the drug permeability experiment. Fig. 3 . Relationship between f u,br and (A) P vivo /P app ; and (B) P vivo /P e . Regression analysis included all compounds (n = 27). P vivo values used for the different ratios were taken from Summerfield et al. (2007) [6] . calculation method, P vitro was calculated in presence and absence of GC for 3 different compounds (i.e. carbamazepine, diazepam and chlorpromazine) characterized by different f u,br (Table 4) (Fig. 5) .
As expected, the presence of GC during the in vitro permeability experiment did not resulted in a significant difference between P vitro (with and without GC) for compounds with a relatively high f u,br , such as carbamazepine. In contrast, the P vitro of diazepam and chlorpromazine, two compounds with a relatively low f u,br , is higher in presence of GC during the BBB permeability experiment than in their absence (Fig. 5 ). This result illustrates that a difference between P e or P app and P vitro is not an effect of the use of a different calculation method of BBB permeability, but rather reflects the effect of brain tissue binding on the distribution of the compound in the in vitro assay.
Indeed, the difference in brain tissue binding affinity for carbamazepine, diazepam, and chlorpromazine, indicated by their f u,br , is also reflected in vitro by the mass balance (MB). In presence of GC, the MB is much lower for chlorpromazine than for diazepam and carbamazepine (Table 4 ). This poor recovery of chlorpromazine in the presence of GC (and to a lower extent of diazepam) reflects the sequestration of the compound within the bBCEC and GC, as the MB of the three compounds in the conditions without either bBCEC or GC does not suggest a strong binding to plastic.
Altogether, our results support that permeability in vivo is a composite function of both permeability across the BBB and tissue binding [4, 6] . This can be illustrated by compounds such as chlorpromazine, which has a high permeability in vivo (i.e. P vivo = 17.40 × 10
) but one of the lowest permeability in vitro (i.e. P e = 2.51 × 10
). The reason for this discrepancy is not necessarily that the in vitro prediction based on the calculation of P e is wrong, but simply that when chlorpromazine is assessed in vivo, a large portion may be associated with the endothelial cell wall. Therefore, when the whole brain is subsequently homogenized, some of the compound associated with the endothelial cell wall, will be erroneously interpreted as having permeated the BBB. In this in vivo dataset, the total brain concentration of a compound was corrected based on the apparent brain distribution volume of atenolol to compensate for drug contained in the capillary vascular space [6] . Atenolol is a drug that does not significantly accumulate in brain tissue during the time course of the experiment.
In fact, in vitro MB calculations indicate that a large portion of chlorpromazine is associated with the bBCEC, as shown by the low recovery in presence of bBCEC and this even in absence of GC. In complete absence of cells (i.e. bBCEC and GC), the recovery of chlorpromazine in this format was close to 100% and demonstrated the absence of non-specific binding to plastic. Consequently, it may very well be the case that chlorpromazine is slowly diffusing across the BBB, as the in vitro permeability data suggests.
By combining in vitro permeation across the brain endothelium and binding to brain tissue, this new method (i.e. P vitro ) offers an improved [6] , obtained by brain perfusion in rodents, and in vitro BBB permeability, obtained by the new in vitro method (P vitro ) for all 27 compounds under study. correlation with in vivo data, that we obtained from literature [6] . Although this can be seen as an advantage, it should be noted that the use of the traditional in vitro BBB permeability assay could still be valuable as it assesses the BBB permeability without accounting for non-specific binding to brain tissue. This is important information to consider while trying to integrate pharmacokinetic parameters into a coherent model of brain penetration and distribution.
Conclusion
This study provides a better understanding of the use of in vitro BBB models as a tool to predict brain exposure in vivo. In this study, 27 CNS compounds were assessed for their BBB permeability in vitro, the latter being compared with in vivo permeability values obtained from literature [6] . A lack of correlation for highly lipophilic compounds (and a very low f u,br ) is observed when using the traditional method to assess BBB permeability in vitro, which suggests a rather poor predictive power of the traditional permeability assay. As a remark, it should be stated that this bovine BBB model has been used both at the University of Artois and in-house at AstraZeneca (former local DMPK group, Sö-dertälje, Sweden) for more than a decade to predict BBB permeability of compounds [19] . For this, it is likely that numerous compounds having the same characteristics as chropromazine (i.e. highly lipophilic, very low MB) have been screened in this assay. However, as a rule of control, bBCEC integrity and MB were and are always assessed prior the use of the obtained experimental data in permeability calculations. No permeability calculation was performed when the MB was having a value lower than 80%, as a poor MB could be an indication of several factors e.g. intracellular accumulation of the compound, metabolization of the compound within the endothelium or a lack of accuracy of the used quantification method. Consequently, the resulting poor predictive value obtained by the in vitro BBB model compared to the in vivo permeability could not be identified.
It is only by categorizing compounds based on their f u,br that the observed discrepancy could be identified. This shows and confirms what was already published by several authors, that brain tissue binding is influencing the rate of brain penetration for highly lipophilic compounds [6, 10, 11] . This suggests that the lack of correlation between in vitro and in vivo permeability values is not necessarily due to a poor in vitro permeability assay, but rather to the difference in experimental design. The traditional in vitro permeability assay lacks brain tissue and so, provides no possibility for compounds to bind to brain tissue. The contrary is true in case of the in-situ brain perfusion method, where compounds face the brain parenchyma after passing the BBB. By making use of GC to mimic brain tissue binding in vitro, the method that is introduced here provides in vitro BBB permeability values that better correlate with in vivo permeability values. These results highlight the influence of brain tissue binding, which is sometimes neglected in similar studies and might therefore facilitate in vitro to in vivo extrapolation, as well as the integration of in vitro data into physiologically based pharmacokinetic models of CNS drug distribution.
The recent development of in vitro BBB models in which bBCEC are cultivated in close proximity with other brain cells such as brain pericytes [20] or neuronal progenitors [21] might also benefit of the introduction of the P vitro calculation method, as the same cells (e.g. brain pericytes, neuronal progenitors, etc.) used to induce BBB characteristics could be used to mimic possible brain tissue binding. Finally, the calculation of P vitro in presence and absence (i.e. uncoupling with nonspecific binding) of the brain cells in these assays might facilitate the clarification of the influence of brain tissue binding on the distribution of different compounds across the BBB. 
